Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
Organogenesis announced peer-reviewed publication of PREPARE trial results for PuraPly AM in the Journal of Wound Care. The randomized controlled trial met its primary endpoint, showing statistically significant improvements in 12-week wound closure for hard-to-heal diabetic foot ulcers versus standard of care alone.
Key figures
- Drug Name
- PuraPly AM (PCMP)
- Phase Of Trial
- Prospective, multicenter randomized controlled trial
- Endpoint
- primary endpoint achieved
- Timepoint
- wound closure at 12 weeks
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.